Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

← catalyst calendar

NCT07392892 · readout in 1,797 d

Sponsored by Pfizer (industry) · PFE — their whole pipeline →.

Phase

Phase 2/3

Status

Recruiting

Study type

Interventional

Design

Randomized · Double · Treatment

Enrollment

840estimated

Sites

Countries

China, Israel, Italy +5

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-05-14

actual

When the study began enrolling

Primary completion

2031-07-22

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2032-07-21

estimated

The whole study's end, after follow-up

First posted

2026-02-06

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-17

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma
Metastatic Gastric Cancer
Gastroesophageal Junction Cancer
Esophageal Adenocarcinoma

Interventions

Biological: PF-08634404 — also filed as SSGJ-707
Drug: Chemotherapy
Biological: Nivolumab

Primary outcomes

what the primary-completion date above is the date OF

Phase 2: Confirmed Objective response rate (ORR) using RECIST 1.1 as assessed by investigator

measured Approximately 4 years

Phase 2: Number of participants with treatment-emergent adverse events

measured Through 90 days after the last study intervention; Approximately 4 years

Phase 3: Progression Free Survival (PFS) using RECIST 1.1 as assessed by BICR

measured Approximately 4 years

Phase 3: Overall Survival (OS)

measured Approximately 4 years

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed